- Home
- EPM vs KLRS Comparison
EPM vs KLRS Comparison
Compare EPM & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPM | KLRS |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.2M | 132.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPM | KLRS |
|---|---|---|
| Price | $4.24 | $6.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.83 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 350.9K | 71.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 11.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $43,229,621.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $84.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $2.14 |
| 52 Week High | $5.70 | $11.88 |
Technical Indicators
Market Signals| Indicator | EPM | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 46.11 |
| Support Level | $3.19 | $4.35 |
| Resistance Level | $4.27 | $7.18 |
| Average True Range (ATR) | 0.15 | 0.64 |
| MACD | -0.05 | 0.14 |
| Stochastic Oscillator | 8.53 | 67.37 |
Price Performance
Historical ComparisonAbout EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.